Physician profile
Alex David Meyer
NPI 1417525742
$2,842.38
in general payments reported to CMS, 2019-2025
22 companies · $709 in 2025
The $709 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $642 · 2023: $584 · 2024: $736 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $585.20 | 2022-2025 | |
| Alcon Vision LLC | $366.95 | 2022-2025 | Rocklatan, Simbrinza, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $270.47 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Astellas Pharma US INC | $197.28 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $171.81 | 2023-2025 | Syfovre |
| Abiomed | $146.40 | 2021 | |
| Genentech USA, INC. | $141.87 | 2024-2025 | Vabysmo |
| Allergan, INC. | $117.96 | 2022 | |
| Haag-Streit USA, INC. | $115.42 | 2022 | |
| Horizon Therapeutics Plc | $109.91 | 2022 | |
| Alimera Sciences, INC. | $100.49 | 2023-2024 | Iluvien, Yutiq |
| Johnson & Johnson Vision Care, INC. | $92.77 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $75.20 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $70.38 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $63.38 | 2023-2024 | Eylea Hd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $59.83 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $49.73 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $28.05 | 2025 | Yutiq |
| Ivantis, INC | $24.62 | 2021 | |
| Oyster Point Pharma, INC. | $21.03 | 2022 | |
| Amgen INC. | $20.91 | 2025 | Pavblu |
| Eyevance Pharmaceuticals LLC | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.